Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

3,000 volunteers to reveal hidden heart risks in qatar

NCT ID NCT07675928

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study follows 3,000 adults in Qatar—both citizens and long-term residents—to track how cardiometabolic conditions like diabetes and heart disease develop over time. Participants are grouped by blood sugar status (normal, pre-diabetes, or diabetes) and monitored for major cardiovascular events such as heart attacks and strokes. The goal is to identify risk factors and improve prevention strategies for these common diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal key risk factors and patterns that help prevent heart attacks and strokes in diverse populations.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited at Hamad Medical Corporation

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Qataris * Long-term residents (≥15 years of residence in Doha) who are not planning to leave Qatar voluntarily within the next 5 years. * Age ≥18 years. * English or Arabic speaker. * Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk. 1. ASCVD: ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes. i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories: 1. Coronary Artery Disease (CAD) * Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI)) * Stable or unstable angina with angiographic stenosis ≥50% * History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG)) 2. Cerebrovascular Disease * Ischemic stroke or transient ischemic attack (TIA) * Symptomatic carotid artery stenosis ≥50% or prior carotid intervention 3. Peripheral Arterial Disease (PAD) * Intermittent claudication with objective evidence of arterial obstruction * Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI \<0.9 4. Aortic Atherosclerotic Disease •Aortic aneurysm (abdominal or thoracic) of atherosclerotic origin ii.Unequivocally Documented ASCVD on Imaging: <!-- --> 1. Coronary artery calcium (CAC) score \>100 Agatston units or \>75th percentile for age and sex 2. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery 3. Carotid ultrasound or angiography showing plaque or ≥50% stenosis 4. Lower-limb CT/MR/Doppler angiography showing atherosclerotic plaque or stenosis ≥50% 2. Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines): * 10-year fatal/non-fatal ASCVD risk ≥10% using SCORE2 (ages 40-69), or ≥15% using SCORE2-OP (≥70 years) * Severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² ii.In diabetic patients (ESC 2023 Diabetes \& CVD Guidelines): * 10-year cardiovascular risk ≥20% using SCORE2-Diabetes * Severe target organ damage: <!-- --> 1. eGFR \<45 mL/min/1.73m² (regardless of albuminuria) 2. eGFR 45-59 mL/min/1.73m² with microalbuminuria (UACR 30-300 mg/g) or proteinuria (UACR \>300 mg/g) 3. Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy) Exclusion Criteria: * Type 1 diabetes or monogenic diabetes (e.g., MODY). * Pregnancy (self-reported). * Active cancer, under medical or radiation therapy or terminal, or cancer in remission \< 1 year. * Chronic immune or chronic infectious diseases. * End stage renal disease (ESRD) (estimated glomerular filtration rate \<15 mL/min/1.73m²). * Prisoners. * Inability or unwillingness to provide informed consent, including language barriers. * Mental incapacity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hamad Medical Corporation

    Doha, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.